Day One Biopharmaceuticals, Inc. (DAWN) Stock

DAWN logo

Day One Biopharmaceuticals, Inc.

DAWN
Healthcare

Company profile

Day One Biopharmaceuticals reported revenue of $131.16 million for fiscal year 2024, and a net loss of $95.50 million. That is a net profit margin of -72.8% for fiscal year 2024. In Q3 2025 (the quarter ended September 30, 2025) revenue was $39.80 million, down 57.6% from a year before. In Q3 2025 it reported a net loss of $19.73 million, against net income of $37.04 million a year earlier.

What stands out

  • It spent $227.70 million on research and development in fiscal year 2024, more than its revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

Largest shareholders

  • Access Industries, Inc. (New York)12.76%
  • Fidelity Management & Research Co. LLC11.19%
  • BlackRock Advisors LLC8.90%
  • Atlas Venture Life Science Advisors LLC6.34%
  • Vanguard Fiduciary Trust Co.5.70%

Share of the company, as of November 8, 2025

How much revenue does Day One Biopharmaceuticals make?

Day One Biopharmaceuticals reported $131.16 million in revenue for fiscal year 2024. In Q3 2025 revenue was $39.80 million.

What companies are similar to Day One Biopharmaceuticals?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Merck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY), Revolution Medicines, Inc. (RVMD), Exelixis, Inc. (EXEL).

How much does Day One Biopharmaceuticals spend on research and development?

Research and development by fiscal year: FY2020, $9.10 million; FY2021, $43.58 million; FY2022, $85.62 million; FY2023, $130.52 million; FY2024, $227.70 million.

Company Information

SectorHealthcare
IndustryAdditional Cancer Treatment Drugs
FoundedNov 1, 2018
IPO DateMay 26, 2021
IPO StatusPublic
FoundersJulie Papanek Grant, Samuel Blackman
ExchangeNasdaqGS
TimezoneAmerica/New_York (EST)

Contact & Links

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Day One Biopharmaceuticals, Inc. (DAWN)”, data as of Nov 8, 2025, https://dataporium.tech/stocks/DAWN

LinkedInLinkedInXXYouTubeYouTube